Analystreport

KalVista Pharmaceuticals (KALV) had its price target raised by Stifel Nicolaus from $39.00 to $42.00. They now have a "buy" rating on the stock.

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com